Brief: Orgenesis Acquires Control Of Octomera
31/01/2024 14:26
Jan 31 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ACQUIRES CONTROL OF OCTOMERA WITH THE GOAL OF
PROGRESSING ITS DECENTRALIZED IMMUNO-ONCOLOGY PORTFOLIO TO
CLINIC
* ORGENESIS - IN EXCHANGE, METALMARK SHALL GET ROYALTY OF 5%
OF
NET REVENUE OF OCTOMERA'S CELL PROCESSING SERVICES, FOR THREE
CALENDAR YEARS 2025-2027
Source text for Eikon: ID:nGNX5VQtLW
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules